Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Retained Earnings (2016 - 2025)

Haemonetics has reported Retained Earnings over the past 16 years, most recently at $381.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 2.84% year-over-year to $381.1 million; the TTM value through Dec 2025 reached $381.1 million, down 2.84%, while the annual FY2025 figure was $352.2 million, 1088.36% up from the prior year.
  • Retained Earnings for Q4 2025 was $381.1 million at Haemonetics, up from $336.3 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $392.2 million in Q4 2024 and troughed at -$42.7 million in Q2 2024.
  • A 5-year average of $162.1 million and a median of $186.9 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: tumbled 121.17% in 2022 and later soared 1088.36% in 2025.
  • Year by year, Retained Earnings stood at $169.4 million in 2021, then skyrocketed by 32.09% to $223.8 million in 2022, then skyrocketed by 51.98% to $340.1 million in 2023, then grew by 15.33% to $392.2 million in 2024, then dropped by 2.84% to $381.1 million in 2025.
  • Business Quant data shows Retained Earnings for HAE at $381.1 million in Q4 2025, $336.3 million in Q3 2025, and $356.0 million in Q2 2025.